Companion Diagnostics
•25 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (25)
%
| Company | Market Cap | Price |
|---|---|---|
|
Oncomine Dx Target Test and Oncomine Dx Express Test are companion diagnostics enabling rapid genomic profiling.
|
$198.11B |
$524.80
-1.88%
|
|
Companion Diagnostics captures biomarker-based diagnostic tests used to identify patients for targeted therapies.
|
$144.89B |
$202.46
-1.20%
|
|
Zoetis employs companion diagnostics and biomarker-informed approaches to precision animal health.
|
$62.82B |
$141.11
-1.59%
|
|
Signatera functions as a companion diagnostic to guide cancer therapy decisions.
|
$22.07B |
$161.61
+0.94%
|
|
Hereditary cancer screening and biomarker-driven diagnostics align with Companion Diagnostics.
|
$16.69B |
$96.39
-4.47%
|
|
QIAstat-Dx is a platform used in companion diagnostics.
|
$10.49B |
$46.85
-1.10%
|
|
ExoDx Prostate IntelliScore and related tests align with Companion Diagnostics, biomarker-based diagnostic offerings.
|
$8.72B |
$55.63
+6.51%
|
|
Companion diagnostics-style biomarker tests that identify patients most likely to respond to specific therapies.
|
$2.73B |
$34.80
-0.66%
|
|
Companion diagnostics use of clonoSEQ as biomarker in therapy selection and monitoring.
|
$2.03B |
$13.36
-3.68%
|
|
Companion diagnostics / theranostic approach: imaging (²⁰³Pb) used to confirm targeting before therapy.
|
$360.75M |
$4.86
+15.71%
|
|
NIS4 is a diagnostic test classifying patients (companion diagnostic-like utility) enabling patient selection and trial enrollment; LabCorp is commercializing it.
|
$212.11M |
$4.25
-2.29%
|
|
Companion diagnostic test development for Cyclin E1 biomarker is a core asset enabling biomarker-driven therapy.
|
$115.84M |
$1.59
-0.93%
|
|
MCED/MRD testing support therapy selection and biomarker-driven diagnostics, aligning with companion diagnostic category.
|
$86.30M |
$8.36
-4.46%
|
|
CD38-Diagnostic is an in vitro diagnostic tool enabling patient selection, i.e., companion diagnostics.
|
$55.17M |
$15.70
-1.94%
|
|
VeriStrat and related Nodify tests function as biomarker-based diagnostics that inform treatment decisions (companion diagnostics).
|
$53.64M |
$7.32
-6.75%
|
|
Nu.Q Discover is a biomarker profiling platform/service aimed at drug developers, supporting companion diagnostics opportunities.
|
$47.81M |
$0.46
-10.75%
|
|
RADX has diagnostic assets (e.g., RAD101) used to identify brain metastases, aligning with companion diagnostic concepts.
|
$46.41M |
$7.03
-5.64%
|
|
Biomarker-based diagnostics used to identify patients for targeted therapies align with Companion Diagnostics.
|
$28.79M |
$19.04
-7.65%
|
|
CNSide provides biomarker-based tests and diagnostic capabilities to guide CNS cancer management.
|
$24.42M |
$0.72
-7.07%
|
|
DRP platform includes a companion diagnostic component, used to identify patients likely to respond to stenoparib.
|
$24.28M |
$1.61
-8.52%
|
|
BE-Smart's biomarker panel positions it within the realm of Companion Diagnostics (biomarker-driven diagnostics).
|
$21.85M |
$0.53
+1.29%
|
|
Diagnostic/biomarker emphasis for measuring microRNA-10b in blood, aligning with companion diagnostics.
|
$8.81M |
$10.56
-1.45%
|
|
ADIL is developing a companion diagnostic to identify patients most likely to respond to AD04.
|
$3.15M |
$0.39
-3.34%
|
|
Can-Fite is developing a biomarker-based blood test kit (A3AR) for patient/tatient stratification (companion diagnostics).
|
$2.66M |
$0.53
-7.02%
|
|
Development of companion diagnostic tests (PC-RAD) and PSMA-targeted diagnostics for precision oncology.
|
$1.67M |
$3.80
+6.74%
|
Loading industry metrics...
Loading comparison data...
